Phase 1-2 Trial of Antisense Olignucleotide Toferson for SOD1 ALS - Annexon Biosciences

Phase 1-2 Trial of Antisense Olignucleotide Toferson for SOD1 ALS - Annexon Biosciences

About
Mission History Leadership Board of Directors Scientific Advisors Contact
Science
Overview Publications
Pipeline
Overview Patient Access
Investors & Media
Corporate Overview News Releases Events and Presentations Annual Reports & Proxy Statements Corporate Governance Stock Information Analyst Coverage SEC Filings FAQs IR Contact
Careers
Overview Values Our Culture Job Opportunities Our Benefits

Contact Us

info@annexonbio.com
650.822.5500

Annexon, Inc.

1400 Sierra Point Parkway, Building C,
2nd Floor
Brisbane, CA 94005

Privacy Policy
Terms of Use

© 2024 Annexon, Inc. All rights reserved.

This website uses cookies to ensure you get the best experience on our website. Learn more